Category: Edwards Lifesciences
Medtronic CEO Omar Ishrak says the medical device company's CoreValve replacement heart valve has captured more than 40% of the U.S. transcatheter aortic valve implant market in just 2 quarters.
Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany
A registry study of early TAVI devices finds that patients with Medtronic's CoreValve were more likely to have aortic regurgitation, but patients with Edwards Lifesciences' Sapien fared worse if they had aortic regurgitation.
Edwards Lifesciences chairman & CEO Michael Mussallem warns Congress that healthcare regulators and payers are cultivating an "alarming and documented decline in U.S. medical innovation."
Edwards Lifesciences boosts its full-year guidance as sales surge in Q2, and the company pads its bottom line with a $750 million settlement from Medtronic.
Edwards Lifesciences (NYSE:EW) bumped its expectations for the year after posting a strong 2nd quarter with significant increases in its sales and profits.
Edwards Lifesciences says it won 510(k) clearance from the FDA for its ClearSight patient monitoring device.
Edwards Lifesciences wins FDA approval for its next-generation Sapien XT transcatheter valve implantation system in high-risk and inoperable patients.